T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is an immune receptor that plays a key role in suppressing T-cell activation and proliferation. As a newly identified checkpoint, it is highly expressed on various immune cells, including CD4+ and CD8+ T cells, NK cells.

Learn about high-throughput antibody expression & production techniques for faster therapeutic research, industrial-scale manufacturing, and improved panel diversity.

Explore antibody therapeutics, from monoclonal antibodies to innovative formats like ADCs & bispecifics, revolutionizing treatment for cancer, autoimmune, and infectious diseases.

The COVID-19 pandemic has reshaped global health strategies, pushing preventive measures to the forefront of public attention. Now, there is a renewed focus on fortifying defenses against future viral threats and ways to improve hospitalization rates. Here, we will explore the latest advancements in post-pandemic prevention strategies and the broader landscape of public health.

Explore the role of bispecific antibodies (bsAbs) in cancer therapy and beyond. Learn how their dual-targeting capability enhances immune responses and overcomes limitations of monoclonal antibodies.

Discover how high-affinity antibodies enhance therapeutic precision, reduce side effects, and improve patient outcomes by targeting disease antigens effectively.

News from the IASLC 2024 World Conference on Lung Cancer (WCLC24) has provided several updates on the clinical trial space for non-small cell lung cancer (NSCLC), with several antibody-based drugs at the forefront. NSCLC is the most common type of lung cancer, accounting for about 85% of all cases.

In August, the US FDA approved Galderma’s Nemluvio (nemolizumab) for adult patients living with prurigo nodularis (PN). Nemluvio is the first approved monoclonal antibody specifically inhibiting the signaling of IL-31, a neuroimmune cytokine that drives multiple disease mechanisms in (PN). Prurigo nodularis is a chronic skin condition that affects approximately 181,000 patients in the United States

Anti-drug antibodies (ADAs) are immune system proteins that can develop in response to therapeutic drugs, particularly biologics like monoclonal antibodies. These biopharmaceuticals have significantly advanced therapies for cancer and autoimmune diseases, but their long-term use can elicit immunogenicity due to repeated administration. The host immune system may recognize epitopes in the biologic drug as foreign, triggering the production of ADAs. This can lead to the formation of drug–ADA immune complexes, which accelerate drug clearance and potentially neutralize the drug's efficacy.

Discover the distinctions between ADC biosimilars, cost-effective alternatives to reference drugs, and ADC isotypes, engineered for specific therapeutic properties. Learn their roles in advanced cancer therapies.

BIO Asia 2024 was held in Taiwan on 24-28 July, 2024. The event brought together bioindustry leaders from North America, Europe and Asia to explore business opportunities and to engage with Taiwan's emerging biotech sector. This year’s theme, Global View, Asian Touch, showcased the opportunities that exist within Asian’s fast-moving economies, its dynamic and innovation-generating biomedical ecosystems, and its globally-connected bioindustry production and value chains.

This month provided not just one, but two FDA approvals for antibody drugs treating patients with paroxysmal nocturnal hemoglobinuria (PNH)!

Explore ADCs, combining monoclonal antibodies with potent drugs for precision cancer treatment. Learn about key components, clinical applications, & future innovations.

Healthspan and lifespan research are two distinct but interconnected areas in aging studies. Lifespan research aims to extend the total number of years an individual lives, seeking interventions that can delay the onset of age-related diseases and prolong life itself. In contrast, healthspan researc

Explore the evolution, applications, and impact of therapeutic antibodies across disciplines, from cancer and autoimmune diseases to infectious & neurological disorders.